Drug Profile
Research programme: epigenetic therapeutics - MorphoSys
Alternative Names: Cancer EPI; CPI-169; CPI-203; CPI-232; CPI-267203; CPI-360; EZH2 inhibitors - MorphoSys; Inhibitors of BET family of bromodomain-containing proteins - MorphoSys ; Inhibitors of histone methyltransferase - MorphoSysLatest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator Constellation Pharmaceuticals
- Developer Constellation Pharmaceuticals; Genentech; MorphoSys; University of Pittsburgh
- Class Antineoplastics; Small molecules
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors; Histone deacetylase inhibitors; Histone methyltransferase inhibitors; Immunomodulators; Ubiquitin-protein ligase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Solid tumours
- Discontinued Cystic fibrosis; Immunological disorders; Inflammation
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Cancer in USA
- 28 May 2022 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 04 Jun 2018 Preclinical development in Cancer is ongoing in USA (unspecified route) (Constellation Pharmaceuticals pipeline, June 2018)